QFRIA

What this means for you

Approved and waiting on proof of use. It will register unless the applicant drops it, and its 23 Nov 2022 filing date already counts against anyone who files later.

Record

Serial number

97690355

Mark type

Word mark

Filed

23 Nov 2022

Published for opposition

25 Jul 2023

Attorney of record

MARILYN F. KELLY

Goods and services

• Class 005 — Pharmaceuticals: Pharmaceutical preparations for human use for the treatment and prevention of cancer, auto-immune diseases, leukemia, lymphoma, multiple myeloma, autoinflammatory disease and tumors; pharmaceutical preparations for human use, namely, immunotherapies for the treatment of cancer and cytokine inhibitory drugs; pharmaceutical and biological preparations for human use for immunotherapy, namely, T cell therapy; pharmaceutical preparations for human use, namely, stem cells for medical or clinical use, all the foregoing excluding pharmaceutical preparations for the treatment of hemophilia

Owner

• Bristol-Myers Squibb Company, Princeton, NJ, US
• Bristol-Myers Squibb Company, New York, NY, US

Board proceedings on this mark

• Extension of Time to Oppose No. 97690355 — Genzyme Corporation v. Bristol-Myers Squibb Company, filed 18 Aug 2023 (Terminated)

Prosecution history

• 09 Sept 2026 — SOU TEAS EXTENSION RECEIVED
• 12 Feb 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
• 12 Feb 2026 — SOU EXTENSION 4 GRANTED
• 12 Feb 2026 — SOU EXTENSION 4 FILED
• 12 Feb 2026 — SOU TEAS EXTENSION RECEIVED
• 27 Aug 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
• 26 Aug 2025 — SOU EXTENSION 3 GRANTED
• 26 Aug 2025 — SOU EXTENSION 3 FILED
• 26 Aug 2025 — SOU TEAS EXTENSION RECEIVED
• 11 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
• 10 Mar 2025 — SOU EXTENSION 2 GRANTED
• 10 Mar 2025 — SOU EXTENSION 2 FILED
• 10 Mar 2025 — SOU TEAS EXTENSION RECEIVED
• 27 Aug 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
• 27 Aug 2024 — SOU EXTENSION 1 GRANTED